Get the Stockscreener App
0.8208
8.40%
-0.0753
After Hours:
.91
0.0892
+10.87%
Sutro Biopharma Inc Stock (STRO) Latest News
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - MM+M Online
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada
This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com
Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com
Array Technologies, Nextracker, Sutro Biopharma - TradingView
Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK
Sutro Biopharma: Revolutionizing Cancer Treatment with Precision Therapeutics - Apna Kal
Sutro Biopharma Presents Promising Late-Stage Data for Luveltamab Tazevibulin in Platinum-Resistant Ovarian Cancer – Apnakal market - Apna Kal
Sutro Biopharma’s Luvelta Shows Promising Data in Late-Stage Ovarian Cancer Study at SGO 2025 - Apna Kal
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - The Manila Times
Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future - StockTitan
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler - Yahoo Finance
Sutro Biopharma Prioritizes ADC Programs Amid Financial Shift - TipRanks
Bay Area biotech company once worth $2B guts staff, departing execs get $600K - SFGATE
Cattle Post Gains on Friday, Helped by Cash Strength - The Globe and Mail
Oppenheimer cuts Sutro Biopharma stock rating to Perform By Investing.com - Investing.com Canada
Oppenheimer cuts Sutro Biopharma stock rating to Perform - Investing.com India
Jefferies cuts Sutro Biopharma target to $8, maintains Buy By Investing.com - Investing.com Canada
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com
Longtime Peninsula biotech to chop half its jobs, CEO exitsSan Francisco Business Times - The Business Journals
Earnings call transcript: Sutro Biopharma Q4 2024 sees stock plunge - Investing.com India
Truist maintains Buy on Sutro Biopharma, removes price target By Investing.com - Investing.com UK
Sutro prioritizes preclinical ADC programs - BioWorld Online
Sutro stock drops as analysts downgrade (STRO:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Higher Premarket Friday -March 14, 2025 at 09:30 am EDT - Marketscreener.com
New ADC focus as Sutro slashes workforce, drops lead drug - The Pharma Letter
This T-Mobile Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8 - Marketscreener.com
Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs - TradingView
Sutro puts lead ADC on hold, cuts staff and changes CEO - pharmaphorum
Wedbush Downgrades Sutro Biopharma to Neutral From Outperform, Adjusts Price Target to $2 From $8 - Marketscreener.com
Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating -March 14, 2025 at 06:39 am EDT - Marketscreener.com
Director buying at Canadian National Railway (CNR) - The Globe and Mail
Sutro Biopharma Names New CEO; Plans to Reduce Workforce by Nearly 50% After Portfolio Review - Marketscreener.com
Fierce Biotech Layoff Tracker 2025: Sutro halves staff; GRObio restructures - Fierce Biotech
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Sutro Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Sutro Biopharma stock down on portfolio review (STRO:NASDAQ) - Seeking Alpha
Sutro Biopharma Announces Strategic Review and Leadership Change - TipRanks
SUTRO BIOPHARMA, INC. SEC 10-K Report - TradingView
Sutro Biopharma shifts focus to ADC pipeline, appoints new CEO By Investing.com - Investing.com Canada
Sutro Biopharma shifts focus to ADC pipeline, appoints new CEO - Investing.com
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline - The Manila Times
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights - The Manila Times
Sutro Biopharma Announces Strategic Portfolio Review and Management Changes, Highlights Financial Results for Full Year 2024 - Nasdaq
Sutro Biopharma Unveils Major Strategic Shift with $317M War Chest Through 2026 - StockTitan
Sutro Biopharma Slashes Workforce 50%, Pivots to Advanced ADC Pipeline with $316M War Chest - StockTitan
CPKC announces US $1.2 billion debt offering - The Globe and Mail
Public market insider buying at Algonquin Power & Util (AQN) - The Globe and Mail
Sutro Biopharma stock hits 52-week low at $1.31 amid market challenges - Investing.com
Eric Sprott buying more Erdene Resource Dev Corp (ERD) - The Globe and Mail
Damon Motors: Smart, Safe, and Sustainable Electric Vehicles - The Globe and Mail
Cattle Mostly Higher on Monday’s Midday - The Globe and Mail
Primo Brands Corporation Announces Secondary Offering of 45,000,000 Shares of Class A Common Stock by an Affiliate of One Rock Capital Partners - The Globe and Mail
Rhumbline Advisers Has $233,000 Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):